Author

A. Kulick

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

E. De Stanchina· 2 shared A. Chow· 1 shared A. Dobrin· 1 shared A. Farillas· 1 shared A. Holland· 1 shared A. Quintanal-Villalonga· 1 shared A. Richards· 1 shared C. A. Klebanoff· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. De Stanchina

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance

L. Chibaya, K. C. Murphy, Y. Lopez-Diaz, K. D. DeMarco, H. Liu, S. Gopalan, M. Faulkner, J. Li, J. P. Morris, Y.-J. Ho, J. Simon, W. Luan, A. Kulick, E. De Stanchina, K. Simin, , M. Ruscetti

This study shows that inhibiting EZH2 enhances pro-inflammatory SASP in pancreatic cancer, improving NK and T cell infiltration and tumor control in mouse models.

bioRxiv · Jun 21, 2022Cancer Biology

CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer

A. Chow, F. Z. Uddin, L. Mangarin, H. Rizvi, A. Dobrin, S. E. Tischfield, A. Quintanal-Villalonga, J. M. Chan, N. S. Shah, V. Allaj, P. Manoj, M. Mattar, M. Meneses, M. Liu, R. Landau, , C. M. Rudin

This study identifies CD39 as a marker for tumor-reactive CD8 T cells in lung cancer, showing its association with clinical outcomes and response to immune checkpoint therapy.

bioRxiv · Jan 24, 2022 · PreprintImmunology